Metagenomi Therapeutics, Inc.

MGXReported to SECin USCIK 0001785279Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Everything we currently hold fits inside that, so nothing is being held back here today. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5
Form 4 lines at Metagenomi Therapeutics, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Reid Laurence—Open-market buy$138117 sharesSep 11, 2026Reid Laurence$138Buy · Sep 11Open-market buy117Sep 11, 2026
Reid Laurence—Open-market buy$23,26319,883 sharesSep 11, 2026Reid Laurence$23,263Buy · Sep 11Open-market buy19,883Sep 11, 2026
Wein MatthewSee RemarksOpen-market sell$415358 sharesSep 10, 2026Wein MatthewSee Remarks$415Sell · Sep 10Open-market sell358Sep 10, 2026
Irish JianSee RemarksOpen-market sell$2,4792,140 sharesSep 10, 2026Irish JianSee Remarks$2,479Sell · Sep 10Open-market sell2,140Sep 10, 2026
Wapnick PamelaChief Financial OfficerOpen-market sell$2,2141,911 sharesSep 10, 2026Wapnick PamelaChief Financial Officer$2,214Sell · Sep 10Open-market sell1,911Sep 10, 2026